3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione | 51959-57-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione
• CAS: 51959-57-0
• 化学式: C₈H₁₃N₃O₂
• mdl: MFCD11052179
• 分子量: 183.21
• InChiKey: NLITZISVKPYCPP-UHFFFAOYSA-N

物化性质

• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  61.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-bromomethyl-7-(2,2-dimethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile 、 3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 4.0h， 生成 7-(2,2-dimethyl-propyl)-6-(3-methyl-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-8-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
  参考文献：
  名称：

  Effect of Cathepsin K Inhibitors on Bone Resorption

  摘要：

  Oil the basis of the pyrrolopyrimidine core structure that was previously discovered, cathepsin K inhibitors having a spiro amine at the P3 have been explored to enhance the target, bone marrow, tissue distribution. Several spiro structures were identified with improved distribution toward bone marrow. The representative inhibitor 7 of this series revealed in vivo reduction in C-terminal telopeptide of type I collagen in rats and monkeys.

  DOI：

  10.1021/jm800626a
• 作为产物：
  描述：

  tert-butyl-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione
  参考文献：
  名称：

  Effect of Cathepsin K Inhibitors on Bone Resorption

  摘要：

  Oil the basis of the pyrrolopyrimidine core structure that was previously discovered, cathepsin K inhibitors having a spiro amine at the P3 have been explored to enhance the target, bone marrow, tissue distribution. Several spiro structures were identified with improved distribution toward bone marrow. The representative inhibitor 7 of this series revealed in vivo reduction in C-terminal telopeptide of type I collagen in rats and monkeys.

  DOI：

  10.1021/jm800626a

文献信息

• [EN] IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE UTILISABLES EN TANT QUE MODULATEURS DE L'ACTIVITÉ TNF
  申请人：UCB PHARMA SA

  公开号：WO2014009295A1

  公开（公告）日：2014-01-16

  A series of imidazo[l,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

  一系列式(I)的咪唑并[1,2-a]吡啶衍生物，作为人类TNFa活性的有效调节剂，因此在治疗和/或预防各种人类疾病方面具有益处，包括自身免疫和炎症性疾病；神经学和神经退行性疾病；疼痛和伤害感知性疾病；心血管疾病；代谢性疾病；眼科疾病；以及肿瘤学疾病。
• [EN] SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS<br/>[FR] COMPOSÉS SPIRO UTILISÉS EN TANT QU'INHIBITEURS DE GLYCOSIDASES
  申请人：ASCENEURON S A

  公开号：WO2020039029A1

  公开（公告）日：2020-02-27

  Compounds of formula (I) wherein A, R, L, Z, Q1, Q2 and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

  式（I）中A、R、L、Z、Q1、Q2和n的含义如权利要求所述，可用于治疗tau病和阿尔茨海默病。
• Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
  申请人：Anikin Alexey Vyacheslavovich

  公开号：US20080207635A1

  公开（公告）日：2008-08-28

  The present invention provides compounds capable of modulating tyrosine kinases, compositions comprising the compounds and methods of their use.

  本发明提供了能够调节酪氨酸激酶的化合物，包括这些化合物的组合物和使用它们的方法。
• Imidazopyridine Derivatives as Modulators of TNF Activity
  申请人：UCB Biopharma SPRL

  公开号：US20150203486A1

  公开（公告）日：2015-07-23

  A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

  一系列的咪唑[1,2-a]吡啶衍生物（I式），是人类TNFa活性的有效调节剂，因此对于治疗和/或预防各种人类疾病具有益处，包括自身免疫和炎症性疾病；神经和神经退行性疾病；疼痛和伤害性疾病；心血管疾病；代谢性疾病；眼部疾病；以及肿瘤性疾病。
• Heterocyclic compounds as TrkA modulators
  申请人：ChemBridge Corporation

  公开号：EP2298770A1

  公开（公告）日：2011-03-23

  The present invention provides compounds capable of modulating tyrosine kinases, compositions comprising the compounds and methods of their use.

  本发明提供了能够调节酪氨酸激酶的化合物、包含这些化合物的组合物及其使用方法。